Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma
- PMID: 18003987
- DOI: 10.1016/j.jvir.2007.07.016
Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma
Abstract
Purpose: To assess the relationship between cumulative hepatic lobar radiation dose and liver toxicities in patients with hepatocellular carcinoma (HCC) treated with multiple sessions of yttrium-90 radioembolization.
Materials and methods: Forty-one patients with HCC (age range, 46-82 years) underwent radioembolization with 90Y. Patients were classified according to the Okuda scoring system. All patients received single liver lobar treatments on two or more occasions according to standard clinical 90Y embolization protocol. Cumulative radiation dose to each liver lobe was measured and patients were followed to assess liver toxicities. Statistical analysis was performed with the Student t test and Kaplan-Meier analysis.
Results: Patients with Okuda stage I disease received more treatments than those with Okuda stage II disease (mean, 2.65 vs 2.24; P<.05). For average cumulative radiation dose, patients with Okuda stage I disease received 247 Gy (range, 88-482 Gy) and those with Okuda stage II disease received 198 Gy (range, 51-361 Gy; P<.05). A total of 13 toxicities occurred in seven patients (16%). Patients with Okuda stage I disease were given a greater cumulative dose than patients with Okuda stage II disease before worsening of liver function: 390 Gy versus 196 Gy (P<.005). For patients with Okuda stage I disease, a higher cumulative radiation dose was associated with occurrence of one or more toxicities: 222 Gy (no toxicities) versus 390 Gy (>or=1 toxicity; P<.005). No correlation between cumulative radiation dose and liver toxicities existed in patients with Okuda stage II disease. The maximum tolerated dose was between 222 and 390 Gy. Median survival times were 660 and 431 days for patients with Okuda stage I and stage II disease, respectively.
Conclusions: Patients with HCC can tolerate high cumulative radiation doses with 90Y therapy. Compared with patients with Okuda stage II disease, patients with Okuda stage I disease tolerate a higher cumulative radiation dose without liver toxicity, but liver toxicities increase with increasing cumulative radiation doses.
Similar articles
-
The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma.J Vasc Interv Radiol. 2005 Aug;16(8):1085-91. doi: 10.1097/01.RVI.0000177063.92678.21. J Vasc Interv Radiol. 2005. PMID: 16105920
-
Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.J Nucl Med. 2000 Oct;41(10):1673-81. J Nucl Med. 2000. PMID: 11037997
-
Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution.Am J Clin Oncol. 2008 Oct;31(5):431-8. doi: 10.1097/COC.0b013e318168ef65. Am J Clin Oncol. 2008. PMID: 18838878 Clinical Trial.
-
Treatment of hepatocellular carcinoma by radioembolization using 90Y microspheres.Dig Dis. 2009;27(2):164-9. doi: 10.1159/000218349. Epub 2009 Jun 22. Dig Dis. 2009. PMID: 19546555 Review.
-
Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers.Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1552-63. doi: 10.1016/j.ijrobp.2004.09.004. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590187 Review.
Cited by
-
Recommendations for the management of yttrium-90 radioembolization in the treatment of patients with colorectal cancer liver metastases: a multidisciplinary review.Clin Transl Oncol. 2024 Apr;26(4):851-863. doi: 10.1007/s12094-023-03299-y. Epub 2023 Sep 25. Clin Transl Oncol. 2024. PMID: 37747636 Free PMC article. Review.
-
Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides.Pharmaceuticals (Basel). 2022 Oct 28;15(11):1339. doi: 10.3390/ph15111339. Pharmaceuticals (Basel). 2022. PMID: 36355512 Free PMC article. Review.
-
Repeated Transarterial Radioembolization Adverse Event and Hepatotoxicity Profile in Cirrhotic Patients With Hepatocellular Carcinoma: A Single-Center Experience.Cureus. 2022 Mar 28;14(3):e23578. doi: 10.7759/cureus.23578. eCollection 2022 Mar. Cureus. 2022. PMID: 35494977 Free PMC article.
-
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds.Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1682-1699. doi: 10.1007/s00259-021-05600-z. Epub 2022 Feb 11. Eur J Nucl Med Mol Imaging. 2022. PMID: 35146577 Free PMC article.
-
Use of X-Ray Fluorescence Microscopy for Studies on Research Models of Hepatocellular Carcinoma.Front Public Health. 2021 Aug 20;9:711506. doi: 10.3389/fpubh.2021.711506. eCollection 2021. Front Public Health. 2021. PMID: 34490194 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical